[go: up one dir, main page]

WO2010070667A2 - Novel process for the preparation of 7-((3-chloro-6-methyl-5,5-dioxo-6,11-dihydrodibenzo(c,f)(1,2) thiazepin-11-yl)amino)heptanoate - Google Patents

Novel process for the preparation of 7-((3-chloro-6-methyl-5,5-dioxo-6,11-dihydrodibenzo(c,f)(1,2) thiazepin-11-yl)amino)heptanoate Download PDF

Info

Publication number
WO2010070667A2
WO2010070667A2 PCT/IN2009/000659 IN2009000659W WO2010070667A2 WO 2010070667 A2 WO2010070667 A2 WO 2010070667A2 IN 2009000659 W IN2009000659 W IN 2009000659W WO 2010070667 A2 WO2010070667 A2 WO 2010070667A2
Authority
WO
WIPO (PCT)
Prior art keywords
formula
tianeptine
compound
preparation
sodium salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2009/000659
Other languages
French (fr)
Other versions
WO2010070667A3 (en
Inventor
Jagadeesh Babu Rangisetty
Manik Reddy Pullagurla
Rajesh Bhudeti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biophore India Pharmaceuticals Pvt Ltd
Original Assignee
Biophore India Pharmaceuticals Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biophore India Pharmaceuticals Pvt Ltd filed Critical Biophore India Pharmaceuticals Pvt Ltd
Priority to EP09817075A priority Critical patent/EP2367806A2/en
Publication of WO2010070667A2 publication Critical patent/WO2010070667A2/en
Publication of WO2010070667A3 publication Critical patent/WO2010070667A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D281/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02Seven-membered rings

Definitions

  • the present invention relates to a novel process for the preparation of sodium 7-((3-Chloro-6-methyl-5,5- dioxo-6,11-dihydrodibenzo(c,f)(1 ,2)thiazepin-11-yl)amino)heptanoate and intermediates.
  • the invention also encompasses isolation of an essentially non-hygroscopic compound which is substantially pure.
  • Tianeptine is currently marketed in Europe as an antidepressant. Unlike the currently used antidepressants which inhibit the serotonin reuptake, Tianeptine enhances serotonin uptake without significant activity at any receptors or other monoamine transporters.
  • the present invention relates to a novel process for the synthesis of Tianeptine.
  • Patents describing synthetic procedures for Tianeptine are listed below.
  • FR 2104728 describes a synthetic process for the preparation of Tianeptine and its therapeutic use.
  • the patent describes the synthesis by the reaction of compound of Formula Il and ethyl-7-aminoheptanoate.
  • EP 0671173 describes the synthesis of Tianeptine by the reaction of compound of Formula III and ethyl- 7-bromoheptanoate.
  • US 6441165 describes a process for the synthesis of the intermediate of 11-amino-3-chloro-6,11-dihydro- 5,5-dioxo-6-methyldibenzo[c,f][1 ,2]thiazepine.
  • One of the objects of the invention was to provide a process for preparing of Tianeptine with improved yields. Another object of the invention was to develop a process devoid of any dinner impurity and provide an improved method for the synthesis of Tianeptine.
  • Yet another object of the invention was to develop a process for Tianeptine which is commercially viable.
  • This invention provides an alternative method for preparing Tianeptine.
  • 3-Chloro-6-methyl-dibenzo[c,f][1 , 2]thiazepin-11 (6H)-one-5,5-dioxide is reduced to give an alcohol which is further chlorinated to give compound of formula IV.
  • the compound of formula IV is condensed with 7-aminoheptanitrile in the presence of a solvent with or without a base to give an intermediate for Tianeptine which is further hydrolyzed to give Tianeptine.
  • One of the objects of the invention was to provide a process for preparing of Tianeptine with improved yields and process.
  • One object of the invention was to develop Tianeptine sodium salt which is essentially non-hygroscopic. Another object of the invention was to develop a process and thereby substantially pure Tianeptine which is devoid of any unsaturated impurity of Formula VII and dimer impurity of Formula VIII and provide an improved method for the synthesis of Tianeptine.
  • This invention also provides an alternative method for preparing Tianeptine sodium salt I from Tianeptine free acid IX.
  • the compound of formula I is prepared by hydrolysis of cyano intermediate compound of Formula-V.
  • the hydrolysis is carried out either in acidic conditions or basic conditions.
  • the reaction is carried out preferably in presence of hydrochloric acid solution.
  • the reaction is preferably carried out at room temperature to reflux conditions. Partial hydrolysis of compound of Formula-V can result in the amido compound of Formula-VI which can be further hydrolyzed either in acidic conditions or basic conditions to provide Tianeptine.
  • synthesis of the compound of Formula-V can be carried out by the reaction of 7-aminoheptanenitrile with compound of Formula IV.
  • the reaction can be performed with or without a solvent and in presence or absence of a base.
  • the reaction can be carried out at temperatures of 10-130 0 C.
  • compound of Formula-V can be synthesized by the reaction of compound of Formula-X and 7-bromoheptanenitrile.
  • the reaction can be performed with or without a solvent and in presence or absence of a base.
  • the reaction can be carried out at temperatures of 10-130 C.
  • the compound of Formula I can be obtained from compound of Formula V either in presence of Acid or basic.
  • the reaction is preferably carried out in presence of hydrochloric acid or sulfuric acid solutions at temperature ranging from 0 0 C to reflux conditions.
  • the compound of Formula Vl can also be converted to Formula I in presence of Acid solutions or basic solutions preferably in presence of hydrochloric acid or sulfuric acid solutions at temperature ranging from 0 0 C to reflux conditions.
  • the compound of Formula I is prepared from compound of Formula-IV in presence of sodium hydroxide and an alcohol or dichloromethane.
  • the reaction is carried out preferably in presence of sodium hydroxide solution added in 0.85 to 1.1 equivalents ratio and preferably 0.9 to 0.95 equivalents with respect to compound of Formula IV.
  • the reaction is carried out at -20 to 65 °C and is preferably carried out at 25-65 0 C.
  • the alcohols employed are methanol, ethanol, propanol, isopropanol, butanol preferably methanol and ethanol.
  • the alkoxide employed is sodium methoxide, sodium ethoxide, sodium propoxide, sodium butoxide and the like and preferably sodium methoxide and sodium ethoxide.
  • the compound of Formula I i.e. Tianeptine sodium is prepared from compound of Formula-X i.e. Tianeptine free acid in presence of sodium alkoxide and an alcohol or dichloromethane.
  • the reaction is carried out preferably in presence of sodium alkoxide added in 0.85 to 1.1 equivalents ratio with respect to compound of Formula IX.
  • the reaction is carried out at -20 to 65 0 C and is preferably carried out at 25-65 °C.
  • the alcohols employed are methanol, ethanol, propanol, isopropanol, butanol preferably methanol and ethanol.
  • the alkoxide employed is sodium methoxide, sodium ethoxide, sodium propoxide, sodium butoxide and the like and preferably sodium methoxide and sodium ethoxide.
  • the sodium salt I once obtained as crude can be slurried in ethyl acetate, toluene or acetonitrile and allowed to stir at -20 to 35 °C and filtered and dried under vacuum to below 1.0% and preferably below 0.5% moisture content, the product becomes essentially non-hygroscopic.
  • a non-hydroscopic product can be prepared by slurry of hygroscopic Tianeptine sodium in a suitable organic solvent preferably ethyl acetate, acetonitrile, and toluene and filtration of the compound.
  • a suitable organic solvent preferably ethyl acetate, acetonitrile, and toluene and filtration of the compound.
  • the compound when dried under vacuum to below 1.0% and preferably below 0.5% moisture content, the product becomes essentially non-hygroscopic.
  • the product prepared by the above process is substantially pure and contains impurities of compound VII and compound VIII in less than 0.1% and is essentially non-hygroscopic.
  • a suspension of compound of Formula III (58.0 g) in dichloromethane (600 ml) is cooled to 0-10 0 C, HCI gas is bubbled through the above suspension for 2-4 hour at 0-10 0 C. Upon completion of starting material, filter the precipitate and dry the solids obtained until constant weight to provide the title compound in 90-95% yield.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

The present invention relates to a novel process for the preparation of sodium 7-((3-Chloro-6-methyl-5,5-dioxo-6,11-dihydrodibenzo(c,f)(1,2)thiazepin-11-yl)amino)heptanoate and intermediates. The invention also encompasses isolation of an essentially non-hygroscopic compound which is substantially pure.

Description

Novel Process for the Preparation of 7-((3-Chloro-6-methyI-5,5-dioxo- 6,11 -dihydrodibenzo(c,f)(1 ,2)thiazepin-11 -yl)amino)heptanoate
FIELD OF INVENTION
The present invention relates to a novel process for the preparation of sodium 7-((3-Chloro-6-methyl-5,5- dioxo-6,11-dihydrodibenzo(c,f)(1 ,2)thiazepin-11-yl)amino)heptanoate and intermediates. The invention also encompasses isolation of an essentially non-hygroscopic compound which is substantially pure.
BACKGROUND
Tianeptine is currently marketed in Europe as an antidepressant. Unlike the currently used antidepressants which inhibit the serotonin reuptake, Tianeptine enhances serotonin uptake without significant activity at any receptors or other monoamine transporters. The present invention relates to a novel process for the synthesis of Tianeptine.
Figure imgf000002_0001
Formula-I
STATE OF THE ART
Patents describing synthetic procedures for Tianeptine are listed below.
FR 2104728 describes a synthetic process for the preparation of Tianeptine and its therapeutic use. The patent describes the synthesis by the reaction of compound of Formula Il and ethyl-7-aminoheptanoate.
EP 0671173 describes the synthesis of Tianeptine by the reaction of compound of Formula III and ethyl- 7-bromoheptanoate.
US 6441165 describes a process for the synthesis of the intermediate of 11-amino-3-chloro-6,11-dihydro- 5,5-dioxo-6-methyldibenzo[c,f][1 ,2]thiazepine.
European Pharmacopeia describes Tianeptine as a hygroscopic product. The content limit for water is about 5%. This poses problems for the handling and formulation of Tianeptine sodium. Hence there is a need for developing a stable and non-hygroscopic form of Tianeptine Sodium. The compound of Formula II, impurity D Ph Eur is 0.1 %.
SUMMARY OF THE INVENTION
One of the objects of the invention was to provide a process for preparing of Tianeptine with improved yields. Another object of the invention was to develop a process devoid of any dinner impurity and provide an improved method for the synthesis of Tianeptine.
Yet another object of the invention was to develop a process for Tianeptine which is commercially viable.
This invention provides an alternative method for preparing Tianeptine. 3-Chloro-6-methyl-dibenzo[c,f][1 , 2]thiazepin-11 (6H)-one-5,5-dioxide is reduced to give an alcohol which is further chlorinated to give compound of formula IV. The compound of formula IV is condensed with 7-aminoheptanitrile in the presence of a solvent with or without a base to give an intermediate for Tianeptine which is further hydrolyzed to give Tianeptine.
Figure imgf000003_0002
Figure imgf000003_0001
Figure imgf000003_0003
Formula-I Formula-V
Figure imgf000003_0004
Formula-VI
Scheme - 1
One of the objects of the invention was to provide a process for preparing of Tianeptine with improved yields and process.
One object of the invention was to develop Tianeptine sodium salt which is essentially non-hygroscopic. Another object of the invention was to develop a process and thereby substantially pure Tianeptine which is devoid of any unsaturated impurity of Formula VII and dimer impurity of Formula VIII and provide an improved method for the synthesis of Tianeptine.
Figure imgf000004_0001
Formula-VII Formula-VIII
This invention also provides an alternative method for preparing Tianeptine sodium salt I from Tianeptine free acid IX.
Figure imgf000004_0002
Formula IX Formula-I
DETAILED DESCRIPTION OF THE SPECIFIC EMBODIMENTS
The compound of formula I is prepared by hydrolysis of cyano intermediate compound of Formula-V. The hydrolysis is carried out either in acidic conditions or basic conditions. The reaction is carried out preferably in presence of hydrochloric acid solution. The reaction is preferably carried out at room temperature to reflux conditions. Partial hydrolysis of compound of Formula-V can result in the amido compound of Formula-VI which can be further hydrolyzed either in acidic conditions or basic conditions to provide Tianeptine.
According to one aspect of the invention synthesis of the compound of Formula-V can be carried out by the reaction of 7-aminoheptanenitrile with compound of Formula IV. The reaction can be performed with or without a solvent and in presence or absence of a base. The reaction can be carried out at temperatures of 10-130 0C.
According to another aspect of the invention compound of Formula-V can be synthesized by the reaction of compound of Formula-X and 7-bromoheptanenitrile. The reaction can be performed with or without a solvent and in presence or absence of a base. The reaction can be carried out at temperatures of 10-130 C.
Figure imgf000005_0001
Formula X
The compound of Formula I can be obtained from compound of Formula V either in presence of Acid or basic. The reaction is preferably carried out in presence of hydrochloric acid or sulfuric acid solutions at temperature ranging from 0 0C to reflux conditions. The compound of Formula Vl can also be converted to Formula I in presence of Acid solutions or basic solutions preferably in presence of hydrochloric acid or sulfuric acid solutions at temperature ranging from 0 0C to reflux conditions.
The compound of Formula I is prepared from compound of Formula-IV in presence of sodium hydroxide and an alcohol or dichloromethane. The reaction is carried out preferably in presence of sodium hydroxide solution added in 0.85 to 1.1 equivalents ratio and preferably 0.9 to 0.95 equivalents with respect to compound of Formula IV. The reaction is carried out at -20 to 65 °C and is preferably carried out at 25-65 0C. The alcohols employed are methanol, ethanol, propanol, isopropanol, butanol preferably methanol and ethanol. The alkoxide employed is sodium methoxide, sodium ethoxide, sodium propoxide, sodium butoxide and the like and preferably sodium methoxide and sodium ethoxide.
According to one aspect of the invention the compound of Formula I i.e. Tianeptine sodium is prepared from compound of Formula-X i.e. Tianeptine free acid in presence of sodium alkoxide and an alcohol or dichloromethane. The reaction is carried out preferably in presence of sodium alkoxide added in 0.85 to 1.1 equivalents ratio with respect to compound of Formula IX. The reaction is carried out at -20 to 65 0C and is preferably carried out at 25-65 °C. The alcohols employed are methanol, ethanol, propanol, isopropanol, butanol preferably methanol and ethanol. The alkoxide employed is sodium methoxide, sodium ethoxide, sodium propoxide, sodium butoxide and the like and preferably sodium methoxide and sodium ethoxide.
According to another aspect of the invention the sodium salt I , once obtained as crude can be slurried in ethyl acetate, toluene or acetonitrile and allowed to stir at -20 to 35 °C and filtered and dried under vacuum to below 1.0% and preferably below 0.5% moisture content, the product becomes essentially non-hygroscopic.
According to another aspect of the invention a non-hydroscopic product can be prepared by slurry of hygroscopic Tianeptine sodium in a suitable organic solvent preferably ethyl acetate, acetonitrile, and toluene and filtration of the compound. The compound when dried under vacuum to below 1.0% and preferably below 0.5% moisture content, the product becomes essentially non-hygroscopic.
The product prepared by the above process is substantially pure and contains impurities of compound VII and compound VIII in less than 0.1% and is essentially non-hygroscopic. EXAMPLES
Example 1
3-Chloro-6-methyldibenzo[c,/][1,2]thiazepin-11 (6W)-ol S,S-dioxide
To a solution of compound of Formula Il (62.5 g) in methanol (500 ml) was charged sodium borohydride (15.04 g) at 0-5 °C. The reaction mass was stirred for 30 minutes at 0-5 0C, and for 30-60 minutes at RT. After the completion of the starting material, the solid was filtered and washed with methanol. The solid compound was dried until constant weight to provide the title compound in 90-95% yield.
Example 2 S^I-Dichloro-βjH-dihydro-e-methyl-δjδ-dioxodibenzoICjfUI^Jthiazepine
A suspension of compound of Formula III (58.0 g) in dichloromethane (600 ml) is cooled to 0-10 0C, HCI gas is bubbled through the above suspension for 2-4 hour at 0-10 0C. Upon completion of starting material, filter the precipitate and dry the solids obtained until constant weight to provide the title compound in 90-95% yield.
Example 3
Z-jniiRSJ-S-Chloro-e-methyl-e.ii-dihydrodibenzoICjfHI.ZJthiazepin-H-yllaminolheptanenitrile S,S-dioxide
To compound of Formula III (50.0 g) in dichloromethane (400 ml) charge triethylamine (18.41 g) and stir the contents for 10 minutes, To the reaction charge 1 -amino, 6-cyanohexane (23.0 g) over a period of 5- 10 minutes and stir for 2-6 hours at RT. Upon completion of starting material wash the organic layer with 5% citric acid solution (3x200 ml). Wash the organic layer with 200 ml brine solution, Distill off the solvent under vacuum, Take the crude to next step without further purification
Example 4 Tianeptine Free Acid
To the crude obtained in example 3, charge cone. HCI (635 ml) to the reaction, Reflux for 18-20 hours and upon the completion of the reaction, cool the reaction mass to 0-5 0C adjust the pH of the reaction mass to ~5.8 to 6.2 using 50% NaOH solution. Once the pH is adjusted cool the reaction mass to 0-5 °C, Stir the reaction at 0-5 0C for 2-3 h, Filter the solids obtained, Extract the aqueous mother liquors with ethyl acetate (3*200 ml). Dry the organic layer with sodium sulfate and distill off the solvent. Combine the solid filtered and the residue obtained, Charge toluene (150 ml) to the combined solids, Heat the reaction mass to 50-60 0C, Stir the mass at 50-60 0C for 2-3 h, Cool the reaction to 0-5 °C for 2-4 h and filter the solids obtained to get a pure solid.
Example 5
Tianeptine Sodium Preparation and Purification
To a solution of methanol (300 ml) and Tianeptine free acid (50 g) is charged 40% NaOH solution (5.042 g of NaOH, 0.126 mol) over a period of 10-20 minutes. Heat the contents of the flask to 60-65 0C for 30 minutes, charge activated carbon (5 g) to the flask and continue heating at reflux for 30-45 minutes, Filter the suspension over a celite pad in hot condition. Distill of methanol and charge dichloromethane (300 ml) to the flask and charge sodium sulfate (30 g) and distill off dichloromethane. Charge 100 ml acetonitrile to the residue cool the reaction mass to -5 to 5 °C and stir the contents for 2-4 hours, Filter the solid dry the compound under vacuum until constant weight.
Example 6
Tianeptine Sodium Preparation
To a solution of methanol (300 ml) and Tianeptine free acid (50 g) is charged 40% NaOH solution (5.042 g of NaOH) over a period of 10-20 minutes at 20-30 0C. Stir the contents of the flask for 30 minutes, charge activated carbon (5 g) to the flask and filter the suspension over a celite pad. Distill of methanol and charge ethyl acetate (500 ml) to the flask cool the reaction mass to -5 to 5 0C and stir the contents for 2-4 hours. Filter the solid dry the compound under vacuum until constant weight. The limit of water is NMT1.0% The product thus obtained is essentially non-hygroscopic. HPLC purity 99.8%. Compound II: 0.05%, Compound 111: Not detected.
Example 7
Tianeptine Sodium Preparation
To a solution of methanol (300 ml) and Tianeptine free acid (50 g) is charged Sodium methoxide (1.1 eq) dissolved in methanol over a period of 10-20 minutes at 20-30 0C. Stir the contents of the flask for 30 minutes, charge activated carbon (5 g) to the flask and filter the suspension over a celite pad. Distill of methanol and charge dichloromethane (300 ml) to the flask and charge sodium sulfate (30 g) and distill off dichloromethane. Charge 100 ml acetonitrile to the residue cool the reaction mass to -5 to 5 0C and stir the contents for 2-4 hours, Filter the solid and dry the compound under vacuum until constant weight. Slurry the dried compound in ethyl acetate and stir at 20 to 35 °C and filter the solid and dry the compound under vacuum. The product thus obtained is essentially non-hygroscopic. HPLC purity 99.7%. Compound II: 0.07%, Compound III: Not detected.

Claims

Claims
1. A process for the preparation of Tianeptine intermediate of formula Vl by the hydrolysis of compound of Formula V.
Figure imgf000008_0001
Formula-V Formula-VI
2. A compound of formula Vl
Figure imgf000008_0002
3. A process for the preparation of Tianeptine by the hydrolysis of the compound of formula V in the presence of an acid or base and optional conversion into its sodium salt.
Figure imgf000008_0003
4. A process for the preparation of compound of formula V by the reaction of compound of formula X with 7-bromoheptanenitrile optionally in the presence of a solvent and base.
Figure imgf000009_0001
Formula-X
Figure imgf000009_0002
5. A compound of formula V
Figure imgf000009_0003
6. A process for the preparation of compound of formula V by the reaction of compound of formula IV with 7-aminohepatanenitrile optionally in the presence of a solvent and base.
7. A process for the preparation of Tianeptine sodium salt from Tianeptine free acid in the presence of sodium hydroxide and an alcohol or dichloromethane.
8. The process of claim 7 wherein the alcohol is methanol, ethanol propanol, isopropanol, butanol preferably methanol.
9. A process for the preparation of Tianeptine sodium salt from Tianeptine free acid in the presence of sodium alkoxide and an alcohol or dichloromethane.
10. The process of claim 9 wherein the alcohol is methanol, ethanol propanol, isopropanol, butanol preferably methanol and the sodium alkoxide is methoxide, ethoxide, propoxide, isopropoxide, butoxide preferably sodium methoxide and sodium ethoxide.
1 1. A process for the preparation of non-hygroscopic Tianeptine sodium salt which involves slurrying the crude Tianeptine sodium salt in a solvent followed by removal of solvent and vacuum drying.
12. The process of claim 1 1 wherein the solvent employed is ethyl acetate or acetonitrile.
13. The process of claims 9 & 1 1 wherein the Tianeptine sodium salt is essentially free of the unsaturated impurity of Formula VII.
14. The process of claims 9 & 1 1 wherein the Tianeptine sodium salt obtained is essentially free of the dimer impurity of Formula VIII.
15. Substantially pure Tianeptine sodium salt.
16. Non-hygroscopic Tianeptine sodium salt.
17. Tianeptine sodium salt which has purity greater than about 99% and the impurities of compound of formula VII and Formula VIII less than 0.1 %.
PCT/IN2009/000659 2008-11-19 2009-11-18 Novel process for the preparation of 7-((3-chloro-6-methyl-5,5-dioxo-6,11-dihydrodibenzo(c,f)(1,2) thiazepin-11-yl)amino)heptanoate Ceased WO2010070667A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09817075A EP2367806A2 (en) 2008-11-19 2009-11-18 Process and intermediates for the preparation of 7-((3-chloro-6-methyl-5,5-dioxo-6,11-dihydrodibenzo(c,f)(1,2) thiazepin-11-yl)amino)heptanoate

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN2841CH2008 2008-11-19
IN2841/CHE/2008 2008-11-19
IN464/CHE/2009 2009-03-03
IN464CH2009 2009-03-03
IN454/CHE/2009 2009-03-03

Publications (2)

Publication Number Publication Date
WO2010070667A2 true WO2010070667A2 (en) 2010-06-24
WO2010070667A3 WO2010070667A3 (en) 2010-10-14

Family

ID=42130483

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2009/000659 Ceased WO2010070667A2 (en) 2008-11-19 2009-11-18 Novel process for the preparation of 7-((3-chloro-6-methyl-5,5-dioxo-6,11-dihydrodibenzo(c,f)(1,2) thiazepin-11-yl)amino)heptanoate

Country Status (1)

Country Link
WO (1) WO2010070667A2 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012143703A1 (en) * 2011-04-18 2012-10-26 Numedicus Limited Dibenzothiazepine derivatives and their use in the treatment of cns disorders
ITMI20111308A1 (en) * 2011-07-14 2013-01-15 Cosma S P A METHOD OF PREPARATION OF TIANEPTINA SALE SODICO
CN103420937A (en) * 2013-06-25 2013-12-04 陕西方舟制药有限公司 Synthesis method of tianeptine sodium
CN105254587A (en) * 2015-10-21 2016-01-20 济南诚汇双达化工有限公司 Preparation method of tianeptine sodium intermediate
CN105924407A (en) * 2016-06-30 2016-09-07 山东诚汇双达药业有限公司 Method for salting tianeptine sodium
WO2017049158A1 (en) * 2015-09-16 2017-03-23 The Trustees Of Columbia University In The City Of New York Carboxylic diarylthiazepineamines as mu-opioid receptor agonists
JP2017507960A (en) * 2014-03-12 2017-03-23 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨークThe Trustees Of Columbia University In The City Of New York A new class of mu-opioid receptor agonists
CN110790723A (en) * 2018-08-02 2020-02-14 北京万全德众医药生物技术有限公司 Synthesis method of tianeptine sodium
CN111004192A (en) * 2019-12-31 2020-04-14 山东诚汇双达药业有限公司 Refining method of tianeptine
KR20200077733A (en) 2018-12-21 2020-07-01 주식회사 한서켐 A process for preparing 3,11-Dichloro-6-methyl -6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide
CN112062733A (en) * 2020-10-30 2020-12-11 南京法恩化学有限公司 Preparation method of tianeptine sodium
CN112062734A (en) * 2020-10-30 2020-12-11 南京焕然生物科技有限公司 Preparation method of tianeptine sodium
CN115819375A (en) * 2022-12-25 2023-03-21 山东诚汇双达药业有限公司 Preparation method of key intermediate of tianeptine sodium

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1269551A (en) * 1969-03-27 1972-04-06 Science Union & Cie New tricyclic derivatives and process for their manufacture
US4835180A (en) * 1986-10-02 1989-05-30 Sterling Drug Inc. N-(ω-cyanoalkyl)aminophenols and use as inhibitors of lipoxygenase activity
FR2716623B1 (en) * 1994-02-25 1996-08-23 Adir Use of a tricyclic derivative for obtaining medicaments intended for the treatment of mnemo-cognitive disorders.
FR2807039A1 (en) * 2000-03-31 2001-10-05 Adir NOVEL PROCESS FOR THE PREPARATION OF 11-AMINO-3-CHLORO-6,11-DIHYDRO-5,5-DIOXO-6-METHYL-DIBENZO [c, f] [1,2] -THIAZEPINE AND APPLICATION TO THE SYNTHESIS OF TIANEPTINE
US7700776B2 (en) * 2006-10-24 2010-04-20 Formosa Laboratories, Inc. Compounds and preparation for montelukast sodium

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103717583A (en) * 2011-04-18 2014-04-09 纽梅迪克斯公司 Dibenzothiazepine derivatives and their use in the treatment of cns disorders
WO2012143703A1 (en) * 2011-04-18 2012-10-26 Numedicus Limited Dibenzothiazepine derivatives and their use in the treatment of cns disorders
CN103717583B (en) * 2011-04-18 2016-02-10 纽梅迪克斯公司 Purposes in dibenzothiazepine * derivative and in the treatment pivot nervous system disorder
US9487492B2 (en) 2011-04-18 2016-11-08 Numedicus Limited Dibenzothiazepine derivatives and their use in the treatment of CNS disorders
ITMI20111308A1 (en) * 2011-07-14 2013-01-15 Cosma S P A METHOD OF PREPARATION OF TIANEPTINA SALE SODICO
CN103420937A (en) * 2013-06-25 2013-12-04 陕西方舟制药有限公司 Synthesis method of tianeptine sodium
EP3116509A4 (en) * 2014-03-12 2017-08-23 The Trustees of Columbia University in the City of New York A new class of mu-opioid receptor agonists
AU2015229258B2 (en) * 2014-03-12 2020-01-30 The Trustees Of Columbia University In The City Of New York A new class of Mu-Opioid receptor agonists
US10183919B2 (en) * 2014-03-12 2019-01-22 The Trustees Of Columbia University In The City Of New York Class of mu-opioid receptor agonists
JP2017507960A (en) * 2014-03-12 2017-03-23 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨークThe Trustees Of Columbia University In The City Of New York A new class of mu-opioid receptor agonists
US10844027B2 (en) 2015-09-16 2020-11-24 The Trustees Of Columbia University In The City Of New York Carboxylic diarylthiazepineamines as mu-opioid receptor agonists
AU2016323977B2 (en) * 2015-09-16 2021-02-25 The Trustees Of Columbia University In The City Of New York Carboxylic diarylthiazepineamines as mu-opioid receptor agonists
WO2017049158A1 (en) * 2015-09-16 2017-03-23 The Trustees Of Columbia University In The City Of New York Carboxylic diarylthiazepineamines as mu-opioid receptor agonists
AU2016323977B9 (en) * 2015-09-16 2021-03-04 The Trustees Of Columbia University In The City Of New York Carboxylic diarylthiazepineamines as mu-opioid receptor agonists
CN105254587B (en) * 2015-10-21 2018-01-09 济南诚汇双达化工有限公司 A kind of preparation method of S-1574 intermediate
CN105254587A (en) * 2015-10-21 2016-01-20 济南诚汇双达化工有限公司 Preparation method of tianeptine sodium intermediate
CN105924407B (en) * 2016-06-30 2019-02-12 山东诚汇双达药业有限公司 A kind of salifying method of S-1574
CN105924407A (en) * 2016-06-30 2016-09-07 山东诚汇双达药业有限公司 Method for salting tianeptine sodium
CN110790723A (en) * 2018-08-02 2020-02-14 北京万全德众医药生物技术有限公司 Synthesis method of tianeptine sodium
KR20200077733A (en) 2018-12-21 2020-07-01 주식회사 한서켐 A process for preparing 3,11-Dichloro-6-methyl -6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide
CN111004192A (en) * 2019-12-31 2020-04-14 山东诚汇双达药业有限公司 Refining method of tianeptine
CN112062734A (en) * 2020-10-30 2020-12-11 南京焕然生物科技有限公司 Preparation method of tianeptine sodium
CN112062733A (en) * 2020-10-30 2020-12-11 南京法恩化学有限公司 Preparation method of tianeptine sodium
CN115819375A (en) * 2022-12-25 2023-03-21 山东诚汇双达药业有限公司 Preparation method of key intermediate of tianeptine sodium

Also Published As

Publication number Publication date
WO2010070667A3 (en) 2010-10-14

Similar Documents

Publication Publication Date Title
WO2010070667A2 (en) Novel process for the preparation of 7-((3-chloro-6-methyl-5,5-dioxo-6,11-dihydrodibenzo(c,f)(1,2) thiazepin-11-yl)amino)heptanoate
CA2726599C (en) Process for treprostinil salt preparation
US8497393B2 (en) Process to prepare treprostinil, the active ingredient in Remodulin®
KR20120016634A (en) Olopatadine Manufacturing Method
CN103450027B (en) The preparation method of cinacalcet hydrochloride
WO2013069025A1 (en) "process for the preparation of dexmedetomidine"
JP2014505721A (en) Improved method for preparing levonorgestrel
CN101723897B (en) Method for synthesizing Ivabradine
EP2367806A2 (en) Process and intermediates for the preparation of 7-((3-chloro-6-methyl-5,5-dioxo-6,11-dihydrodibenzo(c,f)(1,2) thiazepin-11-yl)amino)heptanoate
EP2358369A1 (en) Process for the preparation of substantially optically pure repaglinide and precursors thereof
WO2010021000A2 (en) A process for the preparation of strontium ranelate
US20060264491A1 (en) Telmisartan production process
KR102748251B1 (en) Intermediates and methods for the preparation of linagliptin and its salts
KR102702677B1 (en) Process for Preparation of Fimasartan and Intermediate for Preparing the Same
CN101440067B (en) A kind of preparation method of pharmaceutical intermediate 1-methyl-3-phenylpiperazine
AU2006207789B2 (en) An improved process for the preparation of mycophenolate mofetil
US20120165527A1 (en) process for the preparation of pure paliperidone
CN113072514A (en) Preparation method of cycleanine and intermediate thereof
CN111039838A (en) Preparation method of 3-acetylmercapto-2-methylpropanoic acid
CN110950840A (en) Preparation method of trelagliptin succinate
EP2616464B1 (en) Improved process for the preparation of a precursor of sufentanil base
CN120208891A (en) A preparation method of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
CN102786422B (en) Method for preparing rasagiline mesylate
CN100395246C (en) Process for the manufacture of folic acid antagonists and intermediates thereof
US7446227B2 (en) Process for preparation of 5H-dibenzo[a,d] cycloheptene derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09817075

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009817075

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE